NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $274.58 million. The enterprise value is $294.89 million.
| Market Cap | 274.58M |
| Enterprise Value | 294.89M |
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 34.45 million shares outstanding. The number of shares has increased by 6.40% in one year.
| Current Share Class | 34.45M |
| Shares Outstanding | 34.45M |
| Shares Change (YoY) | +6.40% |
| Shares Change (QoQ) | +0.71% |
| Owned by Insiders (%) | 4.09% |
| Owned by Institutions (%) | 70.90% |
| Float | 25.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.57 |
| Forward PS | 2.68 |
| PB Ratio | 23.89 |
| P/TBV Ratio | 23.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.26, with a Debt / Equity ratio of 6.05.
| Current Ratio | 5.26 |
| Quick Ratio | 3.95 |
| Debt / Equity | 6.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.64 |
Financial Efficiency
Return on equity (ROE) is -96.97% and return on invested capital (ROIC) is -7.46%.
| Return on Equity (ROE) | -96.97% |
| Return on Assets (ROA) | -6.31% |
| Return on Invested Capital (ROIC) | -7.46% |
| Return on Capital Employed (ROCE) | -12.95% |
| Weighted Average Cost of Capital (WACC) | 13.30% |
| Revenue Per Employee | $494,194 |
| Profits Per Employee | -$87,574 |
| Employee Count | 216 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.41% in the last 52 weeks. The beta is 1.93, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -38.41% |
| 50-Day Moving Average | 13.07 |
| 200-Day Moving Average | 14.73 |
| Relative Strength Index (RSI) | 24.40 |
| Average Volume (20 Days) | 507,673 |
Short Selling Information
The latest short interest is 858,343, so 2.49% of the outstanding shares have been sold short.
| Short Interest | 858,343 |
| Short Previous Month | 886,230 |
| Short % of Shares Out | 2.49% |
| Short % of Float | 3.34% |
| Short Ratio (days to cover) | 8.05 |
Income Statement
In the last 12 months, NeuroPace had revenue of $106.75 million and -$18.92 million in losses. Loss per share was -$0.56.
| Revenue | 106.75M |
| Gross Profit | 83.09M |
| Operating Income | -10.19M |
| Pretax Income | -14.55M |
| Net Income | -18.92M |
| EBITDA | -9.91M |
| EBIT | -10.19M |
| Loss Per Share | -$0.56 |
Balance Sheet
The company has $49.23 million in cash and $69.54 million in debt, with a net cash position of -$20.31 million or -$0.59 per share.
| Cash & Cash Equivalents | 49.23M |
| Total Debt | 69.54M |
| Net Cash | -20.31M |
| Net Cash Per Share | -$0.59 |
| Equity (Book Value) | 11.49M |
| Book Value Per Share | 0.33 |
| Working Capital | 68.47M |
Cash Flow
In the last 12 months, operating cash flow was -$12.06 million and capital expenditures -$355,000, giving a free cash flow of -$12.42 million.
| Operating Cash Flow | -12.06M |
| Capital Expenditures | -355,000 |
| Depreciation & Amortization | 286,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.42M |
| FCF Per Share | -$0.36 |
Margins
Gross margin is 77.84%, with operating and profit margins of -9.55% and -17.72%.
| Gross Margin | 77.84% |
| Operating Margin | -9.55% |
| Pretax Margin | -13.63% |
| Profit Margin | -17.72% |
| EBITDA Margin | -9.28% |
| EBIT Margin | -9.55% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.40% |
| Shareholder Yield | -6.40% |
| Earnings Yield | -7.00% |
| FCF Yield | -4.52% |
Analyst Forecast
The average price target for NeuroPace is $12.22, which is 53.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.22 |
| Price Target Difference | 53.33% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 9.54% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.16 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.16 |
| Piotroski F-Score | 3 |